A Retrospective Chart Review Study of Gene-Eden-VIR/Novirin

Status Completed

Clinical Trial Summary

This study measured the changes in health-related complaints by analyzing charts of individuals, who are infected with a latent virus, who have used Gene-Eden-VIR/Novirin.

Clinical Trial Description

The medical community calls the movement from severe to mild disease and from mild to normal health, 'relieving symptoms', and the interventions that cause such movement, drugs, medications, or therapies. The alternative community calls the movement from normal health to superior health, 'boosting health' (or boosting the immune system, or improving your sex drive, or boosting any another well functioning physiological system), and the interventions that cause such movement, natural remedies, dietary supplements, complementary treatments, etc. In general, these interventions aim to achieve superior performance of a normal human body. Of course, boosting the body's normal performance improves many of its capabilities, such as higher resistance to diseases, faster recovery from fatigue, better mental concentration, etc. Each movement presents different objectives. Relieving symptoms represents the ability of an intervention to reduce the frequency, duration, and severity of a disease. In contrast, boosting health represents the ability of an intervention to increase the frequency, duration, and quality of a person's health. In the current study, the investigators would like to measure the changes in health-related complaints by analyzing charts of individuals, who are infected with latent virus, and who have used Gene-Eden-VIR/Novirin. ;

Study Design

Observational Model: Cohort, Time Perspective: Retrospective

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02715752
Study type	Observational
Source	The Center for the Biology of Chronic Disease
Contact
Status	Completed
Phase	N/A
Start date	January 2016
Completion date	March 2016

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT03950414` - A Dose-Escalation Study Evaluating Safety and Tolerability of Viral-Specific T Cells Against CMV in Adult Solid Organ Transplant Recipients	Phase 1
Recruiting	`NCT04690933` - AntiCMV molécules Monitoring in Real-life in Stem Cell Recipients
Withdrawn	`NCT04936971` - Introduction of mTor Inhibitors and the Activation of the Cytomegalovirus (CMV) -Specific Cellular Immune Response	Phase 4
Recruiting	`NCT02671318` - Conversion to Sirolimus: Effects in Cytomegalovirus Infection Recurrence	Phase 4
Completed	`NCT01325636` - Injection of CD4 and CD8 + T Cells Anti-Cytomegalovirus (CMV) or Anti-adenovirus	Phase 1/Phase 2
Recruiting	`NCT00228202` - Genotyping of Cytomegalovirus From Patients in Israel	N/A
Completed	`NCT00031421` - Neonatal CMV-Ganciclovir Follow-up Study	N/A
Completed	`NCT00005496` - Inflammation, Infection, and Future Cardiovascular Risk	N/A
Terminated	`NCT03262194` - Relevance of Gastric Aspirate in HCMV Detection
Completed	`NCT04478474` - Cytomegalovirus (CMV) Viremia and Disease Occurrence in Pediatric Allogeneic Stem Cell Transplantation Recipients
Recruiting	`NCT05370976` - Efficacy and Safety of Cytotect®CP, Hyperimmune Anti-CMV IVIg as CMV Prophylaxis in Patients Developing Acute Grade II-IV GVHD After Allogeneic Hematopoietic Cell Transplantation.	Phase 2
Active, not recruiting	`NCT02943057` - Topical 2% Ganciclovir Eye Drop for CMV Anterior Uveitis / Endotheliitis	Phase 4
Completed	`NCT02538172` - Cell-mediated Immunity for Prevention of CMV Disease	N/A
Completed	`NCT02642822` - The Epidemiologic Study of Human Cytomegalovirus（CMV） in Female Students of Xiamen University	N/A
Completed	`NCT02134184` - The Influence of Chronic CMV Infection on Influenza Vaccine Responses	Phase 4
Completed	`NCT00673868` - Cytomegalovirus (CMV) Specific Cytotoxic T Lymphocytes (CTL) When Used for Prophylaxis Against CMV in Recipients of Allogeneic, T Cell Depleted Stem Cell Transplants	Phase 1
Active, not recruiting	`NCT05089630` - A Study of Safety and Immune Response to Different Doses of a Cytomegalovirus Vaccine in Healthy Adults	Phase 1/Phase 2
Not yet recruiting	`NCT06058858` - Incidence and Risks Factors of CMV Reactivation in Patients Receiving of CAR-T Cells for Acute Leukemia and Lymphoma Relapse, a Cohort Study Analysis
Active, not recruiting	`NCT04904614` - Letermovir Use in Heart Transplant Recipients	Phase 4
Completed	`NCT01986010` - Safety, Tolerability, and Immunogenicity of the Human Cytomegalovirus Vaccine (V160) in Healthy Adults (V160-001)	Phase 1